Abstract:Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Fondazione Gigi & Pupa Ferrari ONLUS Background Calcific aortic stenosis (AS) affects 3% of older adults and lacks medical treatment. The well-known deacetylase Sirtuin1 (SIRT1) could be involved in many pathways linked to AS progression. Sodium-glucose co-transporter 2 inhibitors (SGLT2i), a class of antihyperglycemic agents, have been shown to reduce cardiovascular events and hospitalization for heart failure (possibly via SIRT1), but their possible benefits in AS are not yet known. Purpose Our study aims to uncover if SIRT1 plays a key role in AS progression and if SGLT2i can potentially slow the valve fibro-calcification processes, potentially via SIRT1 modulation. Methods RNA sequencing of control (n=27) and AS (n=39) aortic valves was performed. SIRT1 knockdown (SIRT1-) and overexpressing (SIRT1+) valve interstitial cells (VIC) were generated by CRISPR/Cas9. A calcification assay with or without dapagliflozin (dapa 1uM as SGLT2i) was employed to evaluate valve endothelial cells (VEC) and VIC crass-talk on calcification potential. Patient data were collected from the Lombardy regional healthcare utilization database and diabetic patients who were taking sulphonylureas (sul; not affecting SIRT1) and SGLT2i (acting on SIRT1) were selected. Patients were matched 1:1 by age, sex, and multisource comorbidity score. Kaplan-Maier analysis was used to generate time-to-event curves for aortic valve replacement (AVR) cumulative incidence at 2 years and Cox regression analysis was used to account for confounding effects. Results Whole tissue RNA-seq showed that SIRT1 could be a master regulator of multiple pathways linked to AS. Functional analysis and validations on mutant VIC revealed that inflammation, extracellular-matrix remodeling, and calcification mechanisms are directly regulated by SIRT1. Calcium assays unveiled an increment of calcification in SIRT1- VICs (+50.8%, p<0.01), while SIRT1+ VICs deposited less calcium (-23.6%; p<0.01) compared to wild-type ones. VIC exposed to dapa-treated VEC medium showed reduced calcification (-35.2%, p<0.01). In the dapa-treated VEC medium, we found an increase in NO levels (+19.9%, p<0.01) and VIC treated with an NO donor (detanonate 50uM) showed reduced calcification (-23.2%, p<0.05), while VIC treated with a SIRT1 inhibitor (EX527 25uM) showed an increased calcification (+68.1%, p<0.01). To corroborate these findings, we retrospectively enrolled 233,546 diabetic patients, and after matching, we obtained two groups (sul and SGLT2i) with 37,081 patients each. Adjusted Cox regression analysis revealed that patients taking SGLT2i had a lower AVR incidence than patients taking sulp with a hazard ratio of 0.65 (95%CI 0.47-0.89) resulting in a 35% risk reduction. Conclusion Our data highlights SIRT1 as a key regulator of fibro-calcific processes involved in AS and SGLT2i exhibit potential in slowing AS progression, via SIRT1 modulation. This study unveils promising molecular insights and suggests SGLT2i as a potential therapeutic avenue for AS.

Sirt1 in focus: unveiling molecular insights and therapeutic prospects in calcific aortic stenosis with sglt2i inhibitors

Myocardial SGLT2 expression and cardiac remodeling in patients with severe aortic stenosis: the BIO-AS Study

SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis

Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease

SGLT1 Inhibition Attenuates Apoptosis in Diabetic Cardiomyopathy Via the JNK and P38 Pathway

Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming

Exploring the regulation of circulating factors involved in aortic valve sclerosis onset

Myocardial sodium–glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO‐AS study

Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice

Single cell RNA-seq analysis reveals involvement of the interferon-I pathway and cellular senescence in calcific progression of human aortic valve cells

Longitudinal assessment of coronary plaque regression related to sodium-glucose cotransporter-2 inhibitor using coronary computed tomography angiography

Role of follistatin-like 1 levels and functions in calcific aortic stenosis

Abstract 12300: Sirtuin 1 Prevents Age-associated Aortic Valve Calcification in Vivo

Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin

Potential of dapagliflozin to prevent vascular remodeling in the rat carotid artery following balloon injury

SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study

Unravel novel therapeutic targets in heart failure and associated pulmonary hypertension

Impact of SLGT2 inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac defibrillator

Single-cell RNA-sequencing analysis of aortic valve interstitial cells demonstrates the regulation of integrin signaling by nitric oxide

Echocardiographic evaluation of cardiac remodelling in a cohort of patients with heart failure and reduced ejection fraction treated with dapagliflozin

Dapagliflozin Impedes Endothelial Cell Senescence by Activating the SIRT1 Signaling Pathway in Type 2 Diabetes.